65 related articles for article (PubMed ID: 19209893)
21. Antituberculosis thiophenes define a requirement for Pks13 in mycolic acid biosynthesis.
Wilson R; Kumar P; Parashar V; Vilchèze C; Veyron-Churlet R; Freundlich JS; Barnes SW; Walker JR; Szymonifka MJ; Marchiano E; Shenai S; Colangeli R; Jacobs WR; Neiditch MB; Kremer L; Alland D
Nat Chem Biol; 2013 Aug; 9(8):499-506. PubMed ID: 23770708
[TBL] [Abstract][Full Text] [Related]
22. Discovery and optimization of benzotriazine di-N-oxides targeting replicating and nonreplicating Mycobacterium tuberculosis.
Chopra S; Koolpe GA; Tambo-Ong AA; Matsuyama KN; Ryan KJ; Tran TB; Doppalapudi RS; Riccio ES; Iyer LV; Green CE; Wan B; Franzblau SG; Madrid PB
J Med Chem; 2012 Jul; 55(13):6047-60. PubMed ID: 22691154
[TBL] [Abstract][Full Text] [Related]
23. Structure of Ddn, the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis involved in bioreductive activation of PA-824.
Cellitti SE; Shaffer J; Jones DH; Mukherjee T; Gurumurthy M; Bursulaya B; Boshoff HI; Choi I; Nayyar A; Lee YS; Cherian J; Niyomrattanakit P; Dick T; Manjunatha UH; Barry CE; Spraggon G; Geierstanger BH
Structure; 2012 Jan; 20(1):101-12. PubMed ID: 22244759
[TBL] [Abstract][Full Text] [Related]
24. Substrate specificity of the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis responsible for the bioreductive activation of bicyclic nitroimidazoles.
Gurumurthy M; Mukherjee T; Dowd CS; Singh R; Niyomrattanakit P; Tay JA; Nayyar A; Lee YS; Cherian J; Boshoff HI; Dick T; Barry CE; Manjunatha UH
FEBS J; 2012 Jan; 279(1):113-25. PubMed ID: 22023140
[TBL] [Abstract][Full Text] [Related]
25. Nitroimidazoles for the treatment of TB: past, present and future.
Mukherjee T; Boshoff H
Future Med Chem; 2011 Sep; 3(11):1427-54. PubMed ID: 21879846
[TBL] [Abstract][Full Text] [Related]
26. Structure-activity relationships of antitubercular nitroimidazoles. 3. Exploration of the linker and lipophilic tail of ((s)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl)-(4-trifluoromethoxybenzyl)amine (6-amino PA-824).
Cherian J; Choi I; Nayyar A; Manjunatha UH; Mukherjee T; Lee YS; Boshoff HI; Singh R; Ha YH; Goodwin M; Lakshminarayana SB; Niyomrattanakit P; Jiricek J; Ravindran S; Dick T; Keller TH; Dartois V; Barry CE
J Med Chem; 2011 Aug; 54(16):5639-59. PubMed ID: 21755942
[TBL] [Abstract][Full Text] [Related]
27. The effect of 5-substitution on the electrochemical behavior and antitubercular activity of PA-824.
Bollo S; Núñez-Vergara LJ; Kang S; Zhang L; Boshoff HI; Barry CE; Squella JA; Dowd CS
Bioorg Med Chem Lett; 2011 Jan; 21(2):812-7. PubMed ID: 21168331
[TBL] [Abstract][Full Text] [Related]
28. Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery.
Ekins S; Freundlich JS; Choi I; Sarker M; Talcott C
Trends Microbiol; 2011 Feb; 19(2):65-74. PubMed ID: 21129975
[TBL] [Abstract][Full Text] [Related]
29. The nitroimidazooxazines (PA-824 and analogs): structure-activity relationship and mechanistic studies.
Denny WA; Palmer BD
Future Med Chem; 2010 Aug; 2(8):1295-304. PubMed ID: 21426020
[TBL] [Abstract][Full Text] [Related]
30. Recent Progress in the Discovery and Development of 2-Nitroimidazooxazines and 6-Nitroimidazooxazoles to Treat Tuberculosis and Neglected Tropical Diseases.
Showalter HD
Molecules; 2020 Sep; 25(18):. PubMed ID: 32927749
[TBL] [Abstract][Full Text] [Related]
31. Structure-activity relationships of antitubercular nitroimidazoles. 2. Determinants of aerobic activity and quantitative structure-activity relationships.
Kim P; Kang S; Boshoff HI; Jiricek J; Collins M; Singh R; Manjunatha UH; Niyomrattanakit P; Zhang L; Goodwin M; Dick T; Keller TH; Dowd CS; Barry CE
J Med Chem; 2009 Mar; 52(5):1329-44. PubMed ID: 19209893
[TBL] [Abstract][Full Text] [Related]
32. Structure-activity relationships of antitubercular nitroimidazoles. 1. Structural features associated with aerobic and anaerobic activities of 4- and 5-nitroimidazoles.
Kim P; Zhang L; Manjunatha UH; Singh R; Patel S; Jiricek J; Keller TH; Boshoff HI; Barry CE; Dowd CS
J Med Chem; 2009 Mar; 52(5):1317-28. PubMed ID: 19209889
[TBL] [Abstract][Full Text] [Related]
33. Synthesis, reduction potentials, and antitubercular activity of ring A/B analogues of the bioreductive drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
Thompson AM; Blaser A; Anderson RF; Shinde SS; Franzblau SG; Ma Z; Denny WA; Palmer BD
J Med Chem; 2009 Feb; 52(3):637-45. PubMed ID: 19099398
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and antitubercular activity of 7-(R)- and 7-(S)-methyl-2-nitro-6-(S)-(4-(trifluoromethoxy)benzyloxy)-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazines, analogues of PA-824.
Li X; Manjunatha UH; Goodwin MB; Knox JE; Lipinski CA; Keller TH; Barry CE; Dowd CS
Bioorg Med Chem Lett; 2008 Apr; 18(7):2256-62. PubMed ID: 18358721
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and structure-activity relationships of aza- and diazabiphenyl analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824).
Kmentova I; Sutherland HS; Palmer BD; Blaser A; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA; Thompson AM
J Med Chem; 2010 Dec; 53(23):8421-39. PubMed ID: 21069962
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5h-imidazo[2,1-b][1,3]oxazine (PA-824).
Thompson AM; Sutherland HS; Palmer BD; Kmentova I; Blaser A; Franzblau SG; Wan B; Wang Y; Ma Z; Denny WA
J Med Chem; 2011 Oct; 54(19):6563-85. PubMed ID: 21846109
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
